Intravacc specializes in the development and manufacturing of next-generation vaccines, leveraging its proprietary platforms to address various infectious diseases. The company employs several innovative technologies, including the OMV-Vacc platform, which utilizes Outer Membrane Vesicles (OMVs) derived from gram-negative bacteria. This platform is designed for the creation of prophylactic vaccines and has demonstrated versatility in targeting bacterial, viral, and parasitic infections, as well as applications in oncology and antimicrobial resistance. Intravacc's OMV technology is supported by extensive scientific research, with numerous publications and patents, ensuring a strong foundation for vaccine development.

Additionally, Intravacc utilizes the Cell-Vacc and Con-Vacc platforms, which focus on cell-based and conjugate vaccine technologies, respectively. The Cell-Vacc platform is particularly noted for its use of cGMP-grade Vero and HEK293 cell lines for the production of inactivated virus vaccines, while the Con-Vacc platform is designed for optimized antigen design and conjugation methods. These technologies enable Intravacc to develop a diverse pipeline of vaccine candidates, including those targeting COVID-19 and gonorrhea, while ensuring high safety and efficacy standards through rigorous analytical method development and quality control processes.

Netherlands

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production.  We at Intravacc are fully aware of the challenges on the long road of vaccine development.
We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.
As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.
Part of Utrecht Science Park Bilthoven

Intravacc

Company Details